Drug Approval | December 27, 2022
MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The CRL did not identify any outstanding scientific issues with the product.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
